Kodigepalli Karthik M, Thatcher Kaitlyn, West Toni, Howsmon Daniel P, Schoen Frederick J, Sacks Michael S, Breuer Christopher K, Lincoln Joy
Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Center for Cardiovascular Simulation, Institute for Computational Engineering and Sciences and Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX 78712, USA.
J Cardiovasc Dev Dis. 2020 Dec 16;7(4):57. doi: 10.3390/jcdd7040057.
Heart valves are dynamic structures that, in the average human, open and close over 100,000 times per day, and 3 × 10 times per lifetime to maintain unidirectional blood flow. Efficient, coordinated movement of the valve structures during the cardiac cycle is mediated by the intricate and sophisticated network of extracellular matrix (ECM) components that provide the necessary biomechanical properties to meet these mechanical demands. Organized in layers that accommodate passive functional movements of the valve leaflets, heart valve ECM is synthesized during embryonic development, and remodeled and maintained by resident cells throughout life. The failure of ECM organization compromises biomechanical function, and may lead to obstruction or leaking, which if left untreated can lead to heart failure. At present, effective treatment for heart valve dysfunction is limited and frequently ends with surgical repair or replacement, which comes with insuperable complications for many high-risk patients including aged and pediatric populations. Therefore, there is a critical need to fully appreciate the pathobiology of biomechanical valve failure in order to develop better, alternative therapies. To date, the majority of studies have focused on delineating valve disease mechanisms at the cellular level, namely the interstitial and endothelial lineages. However, less focus has been on the ECM, shown previously in other systems, to be a promising mechanism-inspired therapeutic target. Here, we highlight and review the biology and biomechanical contributions of key components of the heart valve ECM. Furthermore, we discuss how human diseases, including connective tissue disorders lead to aberrations in the abundance, organization and quality of these matrix proteins, resulting in instability of the valve infrastructure and gross functional impairment.
心脏瓣膜是动态结构,在普通人中,其每天开合超过10万次,一生中开合3×10次,以维持单向血流。在心动周期中,瓣膜结构高效、协调的运动由细胞外基质(ECM)成分的复杂网络介导,这些成分提供必要的生物力学特性以满足这些机械需求。心脏瓣膜ECM在胚胎发育期间合成,以分层形式组织,适应瓣膜小叶的被动功能运动,并在一生中由驻留细胞进行重塑和维持。ECM组织的破坏会损害生物力学功能,并可能导致阻塞或渗漏,如果不治疗可能会导致心力衰竭。目前,心脏瓣膜功能障碍的有效治疗方法有限,且常常以手术修复或置换告终,这对包括老年和儿科人群在内的许多高危患者来说会带来难以克服的并发症。因此,迫切需要充分了解生物力学瓣膜失效的病理生物学,以开发更好的替代疗法。迄今为止,大多数研究都集中在细胞水平上描绘瓣膜疾病机制,即间质和内皮谱系。然而,较少关注ECM,而在其他系统中,ECM已被证明是一个有前景的受机制启发的治疗靶点。在这里,我们重点介绍并综述心脏瓣膜ECM关键成分的生物学和生物力学贡献。此外,我们还讨论包括结缔组织疾病在内的人类疾病如何导致这些基质蛋白的丰度、组织和质量异常,从而导致瓣膜结构不稳定和严重功能损害。